Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment.
This study analyzed the macrostructure and microstructure of sleep in 12 parkinsonian patients under basal conditions (T0) and during 1-night treatment (T1) with a new formulation of apomorphine. This new formulation consisted in a microemulsion of apomorphine administered by the transdermal route, able to provide a constant release of the drug over several hours (APO-TD). Sleep analysis at T1 compared with T0 revealed a 16% increment of total sleep time, a 12% increment of sleep efficiency, a 16% increment of stage 3 and 4 non-REM sleep, a 15% reduction of periodic limb movements index, a 22% reduction of arousal index, and a 23% reduction of cycling alternating patterns/non-REM. We conclude that APO-TD may be able to reduce nocturnal anomalous movements, akinesia, and rigidity in Parkinson's disease, and may reduce the disturbed sleep typical of Parkinson's disease.
Divisione di Neurologia e Neuroriabilitazione, IRCCS Istituto Auxologico Italiano, Piancavallo (VB), Italy.
L
L
Priano
G
G
Albani
A
A
Brioschi
G
G
Guastamacchia
S
S
Calderoni
L
L
Lopiano
M
M
Rizzone
R
R
Cavalli
M R
MR
Gasco
F
F
Fraschini
B
B
Bergamasco
A
A
Mauro
D000279:Administration, Cutaneous; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001058:Apomorphine / Q000627:therapeutic use*; D001143:Arousal / Q000187:drug effects; D002851:Chromatography, High Pressure Liquid; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008875:Middle Aged; D009068:Movement / Q000187:drug effects; D010300:Parkinson Disease / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D017286:Polysomnography / Q000379:methods; D012148:Restless Legs Syndrome / Q000188:drug therapy; D012890:Sleep / Q000187:drug effects*; D012891:Sleep Apnea Syndromes / Q000188:drug therapy
D000978:Antiparkinson Agents; D003692:Delayed-Action Preparations; D007980:Levodopa; D001058:Apomorphine